Abstract:Idiopathic pulmonary fibrosis (IPF) is a chronic and lethal interstitial lung disease (ILD) of unknown origin, characterized by limited treatment efficacy and a fibroproliferative nature. It is marked by excessive extracellular matrix deposition in the pulmonary parenchyma, leading to progressive lung volume decline and impaired gas exchange. The chemokine system, a network of proteins involved in cellular communication with diverse biological functions, plays a crucial role in various respiratory diseases. Chemokine receptors trigger the activation, proliferation, and migration of lung-resident cells, including pneumocytes, endothelial cells, alveolar macrophages, and fibroblasts. Around 50 chemokines can potentially interact with 20 receptors, expressed by both leukocytes and non-leukocytes such as tissue parenchyma cells, contributing to processes such as leukocyte mobilization from the bone marrow, recirculation through lymphoid organs, and tissue influx during inflammation or immune response. This narrative review explores the complexity of the chemokine system in the context of IPF and the bleomycin-induced lung fibrosis mouse model. The goal is to identify specific chemokines and receptors as potential therapeutic targets. Recent progress in understanding the role of the chemokine system during IPF, using experimental models and molecular diagnosis, underscores the complex nature of this system in the context of the disease. Despite advances in experimental models and molecular diagnostics, discovering an effective therapy for IPF remains a significant challenge in both medicine and pharmacology. This work delves into microarray results from lung samples of IPF patients and murine samples at different stages of bleomycin-induced pulmonary fibrosis. By discussing common pathways identified in both IPF and the experimental model, we aim to shed light on potential targets for therapeutic intervention. Dysregulation caused by abnormal chemokine levels observed in IPF lungs may activate multiple targets, suggesting that chemokine signaling plays a central role in maintaining or perpetuating lung fibrogenesis. The highlighted chemokine axes (CCL8-CCR2, CCL19/CCL21-CCR7, CXCL9-CXCR3, CCL3/CCL4/CCL5-CCR5, and CCL20-CCR6) present promising opportunities for advancing IPF treatment research and uncovering new pharmacological targets within the chemokine system.

Regulation of Pulmonary Fibrosis by Chemokine Receptor CXCR3.

An Essential Role for Stat3 in Regulating Igg Immune Complex-Induced Pulmonary Inflammation

Inhibition of Pulmonary Fibrosis in Mice by Cxcl10 Requires Glycosaminoglycan Binding and Syndecan-4

FAK-related nonkinase is a multifunctional negative regulator of pulmonary fibrosis.

CXCL16/CXCR6 Axis Promotes Bleomycin-Induced Fibrotic Process in MRC-5 Cells Via the PI3K/AKT/FOXO3a Pathway.

Inhibition of Pulmonary Fibrosis by the Chemokine IP-10/CXCL10

Downregulation of FAK-related non-kinase mediates the migratory phenotype of human fibrotic lung fibroblasts.

C1q/tumor Necrosis Factor-Related Protein-3 Acts As a Target Treating Hepatic Fibrosis

Chitinase 3-Like 1 Suppresses Injury and Promotes Fibroproliferative Responses in Mammalian Lung Fibrosis.

Cxcl6 Antibody Neutralization Prevents Lung Inflammation and Fibrosis in Mice in the Bleomycin Model

Transcriptional Regulation of Increased CCL2 Expression in Pulmonary Fibrosis Involves Nuclear Factor-Κb and Activator Protein-1.

The chemokine CCL1 triggers an AMFR-SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis

The role of the CXCR6/CXCL16 axis in the pathogenesis of fibrotic disease

Acute Pulmonary Inflammation is Inhibited in CXCR3 Knockout Mice after Short-Term Cigarette Smoke Exposure

CD103+ Dendritic Cell - Fibroblast Crosstalk via TLR9 and AHR Signaling Drives Lung Fibrogenesis

MEKK1, JNK, and SMAD3 mediate CXCL12-stimulated connective tissue growth factor expression in human lung fibroblasts

Chemokine (C‐X‐C motif) ligand 14 contributes to lipopolysaccharide‐induced fibrogenesis in mouse L929 fibroblasts via modulating PPM1A

Pro-Fibrotic Effects of CCL18 on Human Lung Fibroblasts Are Mediated via CCR6

The Chemokine System as a Key Regulator of Pulmonary Fibrosis: Converging Pathways in Human Idiopathic Pulmonary Fibrosis (IPF) and the Bleomycin-Induced Lung Fibrosis Model in Mice

Regulatory Role and Translational Potential of CCL11 in Liver Fibrosis.

CCL17 Drives Fibroblast Activation in the Progression of Pulmonary Fibrosis by Enhancing the TGF-β/Smad Signaling.